Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Sonny who wrote (3661)	11/5/2000 5:14:27 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

Sonny, While I don't disagree with you per se, I believe MTSL will raise their numbers when IMGN gives them something to base their price on. To date, they've pretty much known what was going to happen, and it's happened, new partnerships and Analysts coverage. What's happening now wasn't forecast, a major stock offering, and they don't know precisely what will be presented by Dr. Tolcher and company. I believe when the presentation and offering have been concluded, depending on how they're received, MTSL will raise their numbers substantially. The next MTSL should be out the Friday after the Annual Meeting. If information posted on R.B. is correct, that's the same week the offering will be made. If IMGN's price does not falter, I believe that would be a reasonable time for establishing new prices. I know some will say this sounds like hype, but I wouldn't be surprised if the buy under price comes up to $75 and the target goes to $150, JMHO. Gary

To: Sonny who wrote (3661)	11/5/2000 6:49:50 PM
From: RJMC	Read Replies (1) \| Respond to of 5665

You're probably right. One thing I do notice however is with regard to the other stocks that MTSL covers, that they don't seem to be using the same valuation philosophy (such as the STEM Cells recommendation, a company which doesn't even have anything in the pre-clinical stages yet). I noticed that MTSL is quick to raise buy and target limits for the other stocks. But there seems to be a dichotomy when it comes to IMGN. It's hard to imagine IMGN staying in the existing price range. Seems like any kind of news saying that everything is at least going as well as expected in clinical's will drive it up at least 10-20 points (probably a lot more if the news is significant). Any bad news, which is unlikely to the extreme given what Dr. Tolcher said in the IBD article, and the stock wouldn't even be worth recommending. MTSL has always had a history of sticking their necks out with recommendations on good technology. It's just hard for me to see what's holding them back right now. Gonna be a big week, one way or the other. Bob M.

To: Sonny who wrote (3661)	11/8/2000 10:32:01 AM
From: Sonny	Read Replies (3) \| Respond to of 5665

1 observation of concern: The monkey news out, but still volume is not that high on the rise. Does it mean that the short-term game is over for this rally? (In other words: folks who got in way early in the expectation of this news are slowly getting out, and only the naive, retail, generally-too-late crowd getting in now?). Another technical development is that, the gap has developed, that must be eventually filled. Does that mean that, soon a sell-off may commence, perhaps in the absence of any other short term catalyst seen in the near future? I thought the PR would result in some kinda volume spike, but seeing much more subdued action on that front. So, should we take it to mean that we have seen the highs of the trading range for now? All questions of moderation here, trying to contain the excitement in the name of balance, that otherwise might leave some ST traders holding the bag for quite a while involuntarily. All imho of course and something to think about. Another thing: Isn't it the case that typically an abstract of a scientific presentation would necessarily have to include all the salient-points that needs to be presented in a conference? If thats the case, it might put a cold water on the expectation of some, that, the presentation may release some significantly new info that we don't know yet via the abstract pointed to in a post earlier, thats of any additional short term value for the near term price movement. I may be wrong here in this assumption, so comments welcome. regards to all, -/Sonny.